title: Ramucirumab: Boon or bane.
abstract: Ramucirumab is the recent addition to the list of monoclonal antibodies being tried in various malignancies. It has been approved in non-small cell lung cancer, gastric cancer and colorectal cancer after progression of one or more lines of therapies in the advanced setting. Though randomized trials have shown benefit, cost effectiveness is questionable. Moreover, the benefits shown are marginal, putting a question mark over its clinical usage. This review summarizes the latest evidence on ramucirumab.
authors.affiliation: Department of Medical Oncology, DR. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: Pluto_2k3@yahoo.co.in.
authors.forename: Priya
authors.initials: P
authors.lastname: Tiwari
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D003362:Cost-Benefit Analysis; D006801:Humans; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000096662:Ramucirumab
keywords: Gastric cancer; Lung cancer; Ramucirumab; Vascular endothelial growth factor